Modern breeding has driven THC concentrations to 30% or higher, often at the expense of minor cannabinoids. This single-minded pursuit misses cannabis’s therapeutic complexity. Our approach prioritises chemical diversity over maximum potency.
At Puro, our breeding programme specifically targets some of these lesser-known molecules. Thanks to backing from the New Zealand government and other partners, we’ve developed varieties producing exceptional levels of CBC, CBN, CBG, and the variant cannabinoids THCV and CBDV.
Clinical studies have shown CBC (cannabichromene) can have anti-inflammatory and anti-anxiety properties. One of our current products contains 3% CBC alongside 25% THC – a unique profile that provides the entourage effect many patients seek. This combination may offer therapeutic benefits unavailable from high-THC products alone.
CBN (cannabinol) forms when THC degrades over time, traditionally considered undesirable. However, recent research indicates CBN may produce sedating effects that can be valuable for sleep disorders. Our controlled cultivation and processing allows us to optimise CBN levels, potentially useful for specific therapeutic applications.
The variant cannabinoids THCV and CBDV present particularly interesting opportunities. Studies indicate THCV may actually suppresses appetite—opposite to the often-cited cannabis effects—while providing stimulating properties. These variants could support weight management approaches in cannabis therapy.
